aptamers-market

Aptamers Market By Type (Nucleic Acid Aptamers , Peptide Aptamers), By Application (Diagnostics , Therapeutics Development, Research and Development ), By End User ( Academic and Government Research Institutes , Biotechnology and Pharmaceutical Companies , Contract Research, Organizations , Others) - Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

09 Dec 2022 Format PDF icon PPT icon XLS icon Request Sample

Aptamers Market is Expected to Grow at 15% by 2031. Aptamers are chemically synthesized peptides or oligonucleotide molecules that bind to a specific target nucleic acid, protein, or lipid. Aptamers are used in various fields such as drug delivery, diagnostics, and therapeutics. The global aptamers market expected to witness a lucrative growth during the forecast period owing to the growing investment in research and development, technological advancements, growing usage of aptamers in drug delivery and diagnostics. The ethical issues associated with the use of aptamers and stringent regulatory policies for the product approval hinder the market growth.  

The global aptamers market is segmented based on types, applications, and geography. Based on the types, the global aptamers market is segmented into nucleic acid aptamers and peptide aptamers. The nucleic acid aptamers segment is further sub-segmented into DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. In 2023, the market was dominated by nucleic acid aptamers segment owing to the higher preference, introduction of novel nucleic acid aptamers-based drugs such as Macugen and developing of DNA/RNA based aptamer drug such as NOX-A12, REG1. 

Based on applications, in 2023, research and development segmented dominated the global market and expected to retain its dominance during the forecast period. The prime factors for the dominance of segment is the growing use of aptamers in research and development. For instance, Aptagen, LLC is working on the development of aptabodies that overcomes the current restrictions of traditional pharmaceutical drug discovery process. 

In 2023, North America led the global aptamers market owing to rapid technological advancements and rising funding & investment to the development of aptamers. Furthermore, the domicile of the key players such as Aptagen, Inc., Regado Biosciences, Inc., and Somalogic, Inc. contributed to the North America market lead. Furthermore, Asia Pacific holds immense market opportunities due to increasing research & development activities and economic growth and expected to grow during the late phase of the forecast period. In Asia Pacific, the market growth is centered in the major economies such as Japan, China, and India due to supportive government initiatives and rising focus on research and development.

The global aptamers market is highly fragmented due to novel technology and new entrants. Key players hold a substantial position in the market due to better market penetration and geographical outreach. However, many startups are focusing on the development of aptamers to soon enter the competition. For instance, in 2017, Base Pair Biotechnologies, Inc., a provider of custom aptamers discovery and development services, received US$ 3.2 million in series A-3 financing round. Thus, entry of new players accounts for the technological advancement thereby contributing to the global aptamers market growth.

Aptamers Market Global Dynamics

Drivers: Rising awareness of the advantages of aptamers over antibodies

Restrains: Low market acceptance as compared to antibodies

Opportunities: Growth in the venture capital funding for research on aptamers

Challenges: Shortage of skilled & trained professionals


Recent Developments

  • In March 2023, SomaLogic announced the initiation of assaying samples using SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study by analyzing 210 million protein measurements from 30,000 samples. This will help researchers in predicting cancer by better understanding its nature, which in turn may contribute to market growth by addressing the increased demand.
  • In August 2021, Aptamer Group, Ltd. and BizCom Japan, Inc. entered into a distribution and marketing agreement to market Optimer discovery and development services in Japan.
  • In August 2021, Aptamer Group entered a partnership with ProAxsis Limited. As per the partnership, Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsis’s diagnostic assays
  • In July 2021, Aptamer Sciences, Inc. was selected by the Korean government to support a non-clinical project for a new drug development project for COVID-19 treatment and vaccine and will receive a research grant of about USD 0.51 million for one year through this project.
  • In December 2020 — SomaLogic, Inc. (US) raised USD 81 million from leading life sciences investors Casdin Capital, Farallon Capital Management, and Foresite Capital. This will support the commercialization of the company’s products in clinical and life science markets.
  • In November 2020, SomaLogic, Inc. (US) received funding of USD 121 million to support the expansion and commercialization of its proteomics platform serving the life science and clinical markets.
  • In June 2018, Aptamer Group (UK) received USD 2.2 million from Meneldor, a biopharmaceutical investment company, and other overseas investors. These funds will be utilized to drive pre-clinical discovery programs involving the development of aptamer drug conjugates (ApDCs).
  • In November 2017, Base Pair Biotechnologies, Inc. (US) received USD 3.2 million from investors such as Eventi Capital Partners Inc. (Canada) and BioTex, Inc. (US). This funding will be used to acquire new lab instruments and other technologies to help it expand its cellular and molecular analysis capabilities.

Key Players Identified in Aptamers Market include:

Aptagen, LLC, AM Biotechnologies, LLC, Aptamer Solutions Ltd, Aptamer Sciences, Inc., Aptus Biotech S.L., NeoVentures Biotechnology, Base Pair Biotechnologies, Inc., TriLink BioTechnologies, Inc., Regado Biosciences, Inc., Vivonics, Inc., SomaLogic Inc., Noxxon Pharma, Creative Biogene, Auramer, Bio2bind GmbH, IBA GmbH, Barrick Lab, Donovan Biotechnology, LLC And Others.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Aptamers market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Aptamers market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Type
  • Nucleic Acid Aptamers
    •     DNA-Based Aptamers
    •     RNA-Based Aptamers
    •     XNA-Based Aptamers
  • Peptide Aptamers

Application
  • Diagnostics
  • Therapeutics Development
  • Research and Development

End User
  • Academic and Government Research Institutes
  • Biotechnology and Pharmaceutical Companies
  • Contract Research
  • Organizations
  • Others

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Aptamers market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Aptamers market?
  • Which is the largest regional market for Aptamers market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Aptamers market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Aptamers market worldwide?
Choose Licence Type
$4500
$6500
$9000
Why Acute
View Other Reports